Pharmacosmos was founded in Denmark in 1965 by Henry Marinus Christensen, M.D., Ph.D.
Operations
Pharmacosmos' corporate headquarters, manufacturing facilities and research laboratories are located in Holbaek, Denmark (Scandinavia). The company has its own marketing, sales and services operations in Denmark and US, UK, Ireland, Germany, Sweden, Norway and China.[2] In other geographies, the company partners with other pharmaceutical companies responsible for local marketing, sales and distribution of its pharmaceuticals brands. The company does not disclose its revenues.[citation needed]
The company has an ongoing clinical development program aimed at improving treatment options for patients with iron deficiency anemia. In 2010, Pharmacosmos' clinical program included three international clinical studies focused on treatment of iron deficiency anemic patients within nephrology, gastroenterology and hematology/oncology.[3][4][5]
Products
Monofer
Monofer is a treatment for iron deficiency anemia. The generic name of Monofer is iron isomaltoside 1000, developed by Pharmacosmos. Monofer was approved in December 2009 in 22 European countries for treatment of iron deficiency anemia in patients with varying underlying conditions.[6][7] Monofer is approved with a wide dose range and no test dose requirement, allowing iron repletion in a single IV dose if a Total Dose Infusion is given in certain clinical situations.[8] This has to be given in a hospital due to increased risks of reaction. If the patient requires a dose over 20 mg/kg of idealised body weight a second dose has to be given after waiting a week.[9]
Cosmofer
Cosmofer is a treatment for iron deficiency anemia. The generic name of Cosmofer is low molecular weight iron dextran. Cosmofer was approved in 2001 and is available in more than 45 countries worldwide. It has a lower incidence of dextran-induced analphylaxis than older dextran-based products, although still requires a test dose.[10]
Uniferon
Uniferon is for the treatment and prevention of iron deficiency anemia in animals. The generic name for Uniferon is iron dextran. Its approved by health authorities in Europe, Asia and in the U.S. by Food and Drug Administration (FDA).[11]
Dextrans
Pharmacosmos is one of the world leaders within production and fractionation of carbohydrates in particular Dextran.[12] Pharmacosmos has a unique water-based technology and production platform for polymer fractioning and derivative synthesis.
^Sinha, S.; Kalra, P. (2010). "Treating the Anemic Oncology Patient with Intravenous Iron: Why, When, and How?" (PDF). European Journal of Clinical & Medical Oncology. San Lucas Medical. 2 (1): 113.
^"Pharmacosmos' Monofer Receives Approval for Treatment of Iron Deficiency Anemia". Pharmacosmos.com. Retrieved 2010-02-20.
^"Medscape Medical: New Iron Preparation Allows Iron Repletion in Single IV Dose". Medscape.com. Retrieved 2010-08-18.
^"Monofer 100mg/Ml solution for injection/Infusion - Summary of Product Characteristics (SMPC) - (Emc)".
^"CosmoFer - Summary of Product Characteristics (SMPC) - (Emc)".
^"Uniferon - Quality iron for your piglets". www.uniferon.com. Retrieved 2020-11-17.
^"The Global Leader in Pharmaceutical Dextran | Pharmacosmos Dextran". www.dextran.com. Retrieved 2020-11-17.
December 31, 2022
pharmacosmos, pharmaceutical, company, specialized, treatment, iron, deficiency, anemia, stypeprivateindustrypharmaceuticals, healthcarefounded1965headquartersholbaek, denmarkkey, peopletobias, christensen, president, jacob, tolstrup, chairman, board, products. Pharmacosmos is a pharmaceutical company specialized in treatment of iron deficiency anemia 1 Pharmacosmos A STypePrivateIndustryPharmaceuticals HealthcareFounded1965HeadquartersHolbaek DenmarkKey peopleTobias S Christensen President and CEO Jacob Tolstrup Chairman of the Board ProductsMonofer Cosmofer Uniferon Pharmacosmos DextransNumber of employees500 2020 Websitewww pharmacosmos com Contents 1 Company profile 1 1 Operations 1 2 Manufacturing facilities 1 3 Research and development 2 Products 2 1 Monofer 2 2 Cosmofer 2 3 Uniferon 2 4 Dextrans 3 See also 4 ReferencesCompany profile EditPharmacosmos was founded in Denmark in 1965 by Henry Marinus Christensen M D Ph D Operations Edit Pharmacosmos corporate headquarters manufacturing facilities and research laboratories are located in Holbaek Denmark Scandinavia The company has its own marketing sales and services operations in Denmark and US UK Ireland Germany Sweden Norway and China 2 In other geographies the company partners with other pharmaceutical companies responsible for local marketing sales and distribution of its pharmaceuticals brands The company does not disclose its revenues citation needed Manufacturing facilities Edit Pharmacosmos manufacturing facility is approved according to current Good Manufacturing Practice GMP by the European Medicines Agency EMA and by the U S Food and Drug Administration FDA Research and development Edit The company has an ongoing clinical development program aimed at improving treatment options for patients with iron deficiency anemia In 2010 Pharmacosmos clinical program included three international clinical studies focused on treatment of iron deficiency anemic patients within nephrology gastroenterology and hematology oncology 3 4 5 Products EditMonofer Edit Monofer is a treatment for iron deficiency anemia The generic name of Monofer is iron isomaltoside 1000 developed by Pharmacosmos Monofer was approved in December 2009 in 22 European countries for treatment of iron deficiency anemia in patients with varying underlying conditions 6 7 Monofer is approved with a wide dose range and no test dose requirement allowing iron repletion in a single IV dose if a Total Dose Infusion is given in certain clinical situations 8 This has to be given in a hospital due to increased risks of reaction If the patient requires a dose over 20 mg kg of idealised body weight a second dose has to be given after waiting a week 9 Cosmofer Edit Cosmofer is a treatment for iron deficiency anemia The generic name of Cosmofer is low molecular weight iron dextran Cosmofer was approved in 2001 and is available in more than 45 countries worldwide It has a lower incidence of dextran induced analphylaxis than older dextran based products although still requires a test dose 10 Uniferon Edit Uniferon is for the treatment and prevention of iron deficiency anemia in animals The generic name for Uniferon is iron dextran Its approved by health authorities in Europe Asia and in the U S by Food and Drug Administration FDA 11 Dextrans Edit Pharmacosmos is one of the world leaders within production and fractionation of carbohydrates in particular Dextran 12 Pharmacosmos has a unique water based technology and production platform for polymer fractioning and derivative synthesis See also EditList of Danish companies List of pharmaceutical companiesReferences Edit Challenge Iron Deficiency amp Anaemia PHARMACOSMOS www pharmacosmos com Retrieved 2020 11 17 Pharmacosmos establishes UK subsidiary after merger with Vitaline Pharmaceuticals UK Ltd Pharmacosmos com Retrieved 2010 08 01 ClinicalTrials gov identifier no NCT01102413 ClinicalTrials gov identifier no NCT01017614 ClinicalTrials gov identifier no NCT01145638 Sinha S Kalra P 2010 Treating the Anemic Oncology Patient with Intravenous Iron Why When and How PDF European Journal of Clinical amp Medical Oncology San Lucas Medical 2 1 113 Pharmacosmos Monofer Receives Approval for Treatment of Iron Deficiency Anemia Pharmacosmos com Retrieved 2010 02 20 Medscape Medical New Iron Preparation Allows Iron Repletion in Single IV Dose Medscape com Retrieved 2010 08 18 Monofer 100mg Ml solution for injection Infusion Summary of Product Characteristics SMPC Emc CosmoFer Summary of Product Characteristics SMPC Emc Uniferon Quality iron for your piglets www uniferon com Retrieved 2020 11 17 The Global Leader in Pharmaceutical Dextran Pharmacosmos Dextran www dextran com Retrieved 2020 11 17 Retrieved from https en wikipedia org w index php title Pharmacosmos amp oldid 1119213262, wikipedia, wiki, book, books, library,
